Loading...
XJSEASC
Market cap22mUSD
Dec 23, Last price  
87.00ZAR
1D
-3.33%
1Q
26.09%
Jan 2017
-96.59%
IPO
-91.82%
Name

Ascendis Health Ltd

Chart & Performance

D1W1MN
XJSE:ASC chart
P/E
1,019.91
P/S
28.80
EPS
0.09
Div Yield, %
0.00%
Shrs. gr., 5y
5.31%
Rev. gr., 5y
-23.38%
Revenues
1.47b
-4.13%
597,439,2121,617,946,4852,816,716,8513,918,432,0006,435,027,0007,736,552,0005,574,499,0006,963,376,0002,229,085,0001,559,458,0001,535,437,0001,472,044,000
Net income
42m
-44.81%
9,481,185137,763,491209,835,544158,733,000283,131,000277,171,000-4,670,386,000-1,000,820,000-1,090,804,000449,200,00075,322,00041,570,000
CFO
-8m
L-94.22%
-56,189,928100,723,38931,263,893-506,213,000368,713,000685,898,000196,593,000224,842,000646,475,000-93,589,000-140,387,000-8,108,000
Dividend
May 10, 201711 ZAR/sh
Earnings
Mar 26, 2025

Profile

Ascendis Health Limited, a health and wellness company, manufactures and distributes healthcare products in South Africa, Cyprus, Spain, Hungary, Romania, and internationally. The company operates through Consumer Health, Pharma, and Medical segments. It offers body and skin products; and natural supplements, multi-vitamin and mineral supplements, micronutrient supplements, nutraceutical supplements, vitamins, minerals, and homeopathic and herbal products under the Bettaway, Chela-Fer, Chela Mag, Compounding Pharmacy, Junglevites, Menacal 7, Nimue, Scitec, Solal, and Vitaforce brand names. The company also provides medical devices, and diagnostic laboratory equipment and consumables for operating theatres, ICUs, trauma units, maternity and general wards, radiology, pathology labs, research and science institutes, etc.; generic pharmaceutical products, antineoplastic agents, antivirals, aromatase inhibitors, anti-infectives; and products for the nervous system, cardiovascular system, dermatological products, and antimalarials, as well as other therapeutic products under the Pharmachem, Reuterina, Sinucon, Clonam, Phlexy, Surgical Innovations, RCA, and The Scientific Group brands. In addition, it exports its products. The company serves pharmacies, retailers, beauticians, and doctors. Ascendis Health Limited was incorporated in 2008 and is based in Johannesburg, South Africa.
URL
https://ascendishealth.com/
IPO date
Nov 22, 2013
Employees
Domiciled in
ZA
Incorporated in
ZA

Valuation

Title
ZAR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
1,472,044
-4.13%
1,535,437
-1.54%
1,559,458
-30.04%
Cost of revenue
1,336,886
1,507,798
1,507,977
Unusual Expense (Income)
NOPBT
135,158
27,639
51,481
NOPBT Margin
9.18%
1.80%
3.30%
Operating Taxes
(1,201)
1,635
(37,303)
Tax Rate
5.92%
NOPAT
136,359
26,004
88,784
Net income
41,570
-44.81%
75,322
-83.23%
449,200
-141.18%
Dividends
Dividend yield
Proceeds from repurchase of equity
101,530
(2,120)
BB yield
-25.37%
0.64%
Debt
Debt current
20,681
31,231
532,355
Long-term debt
82,763
40,036
313,492
Deferred revenue
3,431
22,131
Other long-term liabilities
1,376
(3,431)
(22,131)
Net debt
52,082
(18,234)
574,188
Cash flow
Cash from operating activities
(8,108)
(140,387)
(93,589)
CAPEX
(48,283)
(35,849)
(55,803)
Cash from investing activities
(20,327)
475,724
1,044,809
Cash from financing activities
(31,132)
(450,528)
(1,273,431)
FCF
(3,016)
605,078
6,256,437
Balance
Cash
50,632
85,369
264,037
Long term investments
730
4,132
7,622
Excess cash
12,729
193,686
Stockholders' equity
636,971
1,142,266
804,320
Invested Capital
673,768
558,785
863,175
ROIC
22.13%
3.66%
2.21%
ROCE
20.03%
4.77%
4.76%
EV
Common stock shares outstanding
626,045
606,241
488,361
Price
0.78
18.18%
0.66
-2.94%
0.68
17.24%
Market cap
488,315
22.04%
400,119
20.49%
332,086
17.46%
EV
559,098
961,254
1,308,791
EBITDA
192,206
104,041
131,309
EV/EBITDA
2.91
9.24
9.97
Interest
12,479
62,466
431,247
Interest/NOPBT
9.23%
226.01%
837.68%